The centenary of insulin discovery represents an important opportunity to transform diabetes
from a fatal diagnosis into a medically manageable chronic condition. Insulin is a key …

Diabetes mellitus (DM) is a metabolic disorder that occurs in the body because of decreased
insulin activity and/or insulin secretion. Pathological changes such as nephropathy …

Background Four glucagon-like peptide-1 (GLP-1) receptor agonists that are structurally
similar to human GLP-1 have been shown to reduce the risk of adverse cardiovascular …

Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists
(GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their …

Type 2 diabetes mellitus (T2DM) continues to be a substantial medical problem due to its
increasing global prevalence and because chronic hyperglycemic states are closely linked …

Despite an ever-growing prevalence and increasing economic burden of Alzheimer's
disease (AD) and Parkinson's disease (PD), recent advances in drug development have …

Diabetic nephropathy (DN) is one of the most severe complications of diabetes. However,
due to its complex pathological mechanisms, no effective therapeutic methods (other than …

Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Whilst the prevalence of obesity continues to increase at an alarming rate worldwide, the
personal and economic burden of obesity-related complications becomes ever more …

Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …